GliTTher creates small‑molecule drugs that cross the blood‑brain barrier to selectively inhibit oncogenic drivers in glioma cells, aiming to improve survival while minimizing side effects. Their platform combines advanced genomics, patient‑derived organoid and xenograft models, and companion diagnostic biomarkers to identify responsive patients and accelerate clinical development for neuro‑oncology partners.
Funding
Funding not disclosed
Founders
Product
Problem
Glioma patients face limited treatment options, with existing therapies often providing modest survival benefits and causing significant side effects. Early detection and precise targeting of tumor-specific pathways remain challenging, leading to suboptimal outcomes.
Solution
GliTTher develops molecularly targeted therapies designed to selectively inhibit oncogenic drivers specific to glioma cells. By leveraging advanced genomics and drug design, the company creates small‑molecule agents that cross the blood‑brain barrier and engage tumor‑specific targets while sparing healthy tissue. Preclinical programs focus on optimizing pharmacokinetics, safety, and efficacy to enable rapid progression into clinical trials. The platform also integrates companion diagnostic biomarkers to identify patients most likely to respond, supporting personalized treatment strategies.
Target Audience
Primary customers are neuro‑oncology clinical trial sponsors, academic research centers, and pharmaceutical partners seeking novel glioma‑specific therapeutics.
Features
- Proprietary pipeline for designing blood‑brain barrier‑penetrant small‑molecule inhibitors
- Target validation using patient‑derived glioma organoids and xenograft models
- Integrated biomarker assay suite for patient selection and response monitoring
- Scalable synthesis process ensuring high purity and consistent batch quality
- Early-stage clinical trial design focused on safety, tolerability, and pharmacodynamics in glioma cohorts